Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 8 at 2:00 PM EDT

Register Free →
logo
Get CLEATUSFree Trial

Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Center for Advancing Translational Science (NCATS) is launching the Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe) program to promote research and development of extracellular vesicle (EV)-based therapies within regenerative medicine. These EVs, including exosomes and microvesicles, are pivotal in cell-to-cell communication by transporting proteins, nucleic acids, and lipids, and hold potential to influence tissue repair and regeneration processes. The program aims to facilitate the translation of these naturally occurring, cell-free therapeutic tools into clinical applications, either as direct EV therapies produced under good laboratory practice (GLP) conditions and stored for off-the-shelf use, or as designer EVs tailored to individual patient needs. ExTReMe supports innovative approaches involving the engineering of EVs to deliver therapeutic agents or modulate regenerative signaling pathways, thereby advancing novel treatments in regenerative medicine. The opportunity is forecasted under the authority of the Cures Acceleration Network, with NCATS seeking proposals that align with these goals. For further information, interested applicants can contact Christine Happel, Ph.D., at NCATS. The initiative is part of the Department of Health and Human Services’ commitment through the National Institutes of Health to accelerate translation of promising therapeutics derived from extracellular vesicle research.

General Info

NCATS funds ExTReMe program to develop engineered extracellular vesicle therapies for regenerative medicine.

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUS
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health
Office AddressUS
Contacts
Christine Happel Ph.D. National Center for Advancing Translational Sciences (NCATS
contact@example.gov
+1 (555) 000-0000

Full Description

Show more

The National Center for Advancing Translational Science (NCATS) seeks to advance its mission by advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine.


The main objective of this program, Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe), is to support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. EVs can be further engineered to deliver therapeutic agents or modulate signaling pathways involved in repair/regeneration.


Areas of interest for ExTReMe could include, but are not limited to:

  1. direct EV therapy (stem cell-isolated EVs produced under GLP conditions, and stored as off-the-shelf therapies);
  2. designer EVs (personalized to the individual patient’s needs).


Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network

Similar Contracts

NAICS: 541714
New
Federal
Exosome Purification, Exosomal RNA Purification, and Small RNA-Sequencing ServicesThe National Institutes of Health, in collaboration with the National Institute on Alcohol Abuse and Alcoholism and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, seeks specialized laboratory services to support the POTS clinical research study conducted at NIH in Bethesda, Maryland. The contract requires a qualified provider to process 31 irreplaceable plasma specimens from human participants, performing integrated exosome isolation, exosomal RNA purification, and small RNA-sequencing using Illumina platforms. These tasks must be completed with strict adherence to sample integrity and chain of custody protocols, as the requiring laboratory lacks the validated capacity or bandwidth to perform these procedures in-house within the required timeframe. Each specimen, consisting of 0.5 mL of plasma, must be processed to yield intact exosomes split into multiple aliquots, with exosomal RNA extracted and_QUALITY controlled, and a portion used for downstream sequencing. The contractor is responsible for supplying all personnel, equipment, reagents, and materials necessary to complete the work. The provider must prepare libraries, sequence all 31 samples on the Illumina platform with a target of approximately 20 million raw reads per sample at 1x51 bp, and deliver sequencing data to the government via both physical hard drive and digital download. Basic bioinformatics processing, including read trimming, filtering, and mapping, is also required to ensure analysis-ready outputs. All specimens and resulting materials must be returned to the NIH in accordance with prescribed protocols, maintaining proper documentation and tracking throughout the entire workflow. The solicitation, numbered 75N98026Q00707, is open for response until July 7, 2026, under NAICS code 541714, with no set-aside requirements, and point of contact for inquiries is John Burton at NIH.
National Institutes Of Health Olao

POSTED

4 days ago

DEADLINE

in 8 days
View Details
NAICS: 541714
New
Federal
Exosomal RNA PurificationThe contract titled Exosomal RNA Purification involves the extraction and purification of RNA from isolated exosomes, with a strict requirement for quality control to ensure the RNA is of sufficient integrity and concentration for downstream sequencing applications. This work must be performed under rigorous standards to maintain sample purity and avoid degradation, as the success of subsequent genomic analyses depends entirely on the quality of the purified RNA. The task is classified as a subcontract under NAICS code 541714 and is managed by the National Institutes of Health under the Department of Health and Human Services, with performance expected to occur at a location in Maryland with ZIP code 20892. The opportunity was posted on June 26, 2026, and responses are due by July 7, 2026, at 1:00 PM EST, with no set-aside designation specified.
National Institutes Of Health Olao

POSTED

4 days ago

DEADLINE

in 7 days
View Details
NAICS: 541714
New
Federal
Exosome Isolation from Human PlasmaThe contract titled Exosome Isolation from Human Plasma requires the isolation of intact exosomes from 31 human plasma specimens using validated methodologies such as ultracentrifugation or commercially available kits, with strict adherence to protocols that ensure the biological integrity of the exosomes throughout the process. The work must be performed to meet high standards of purity and yield, supporting downstream research applications that rely on undamaged exosomal content. All procedures must be documented and verified to confirm consistency and reproducibility across all samples. This subcontract is issued under the National Institutes of Health Office of Laboratory Animal Welfare, within the Department of Health and Human Services, with a NAICS code of 541714 for research and development in the physical, engineering, and life sciences. The opportunity was posted on June 26, 2026, and proposals are due by July 7, 2026, at 1:00 PM. The place of performance is designated with a zip code of 20892, indicating the work will be conducted in or near the Washington D.C. metropolitan area. No set-aside classification is specified, and there is no designated point of contact provided for inquiries.
National Institutes Of Health Olao

POSTED

4 days ago

DEADLINE

in 7 days
View Details
NAICS: 541714
New
Federal
Illumina Small RNA SequencingThe contract calls for small RNA sequencing of 31 purified samples using the Illumina platform with single-end reads of 51 base pairs and a target of approximately 20 million reads per sample. The work is to be performed under a subcontract tied to the National Institutes of Health through the Department of Health and Human Services, with a place of performance identified by the zip code 20892. The solicitation was posted on June 26, 2026, and responses are due by July 7, 2026, at 1:00 PM. The NAICS code 541714 indicates the work falls under research and development in the physical, engineering, and life sciences. There is no set-aside designation specified, and the contract does not include detailed contact information or address details beyond the performance location.
National Institutes Of Health Olao

POSTED

4 days ago

DEADLINE

in 7 days
View Details
NAICS: 541714
New
Federal
AJ12--Special Notice | Intent to Sole Source | Biostatistics Support for Prostate Cancer Analysis for Treatment Choice (PATCH) Clinical Trials ConsortiumThe Veterans Health Administration, Network Contracting Office 5, intends to award a sole source contract to CANCER RESEARCH & BIOSTATISTICS for biostatistics support services related to the Prostate Cancer Analysis for Treatment Choice (PATCH) Clinical Trials Consortium. The vendor will deliver expert analytical and consulting services to all member institutions of the Precision Oncology Program for Cancer of the Prostate and select sites within the Lung Precision Oncology Program. The work is essential for advancing clinical trial data interpretation and treatment optimization in prostate cancer research within the VA healthcare system. The contract will be issued under FAR Subpart 13.106-1(b), reflecting the government’s determination that only this vendor possesses the unique expertise required to fulfill the requirement. This notice is not a solicitation for competitive bids, but any capable responsible source may submit a capability statement, proposal, or quotation prior to the deadline of July 12, 2026, at 12:00 PM Eastern Time. The government retains full discretion to determine whether to proceed with sole source award based on any submissions received. The action is categorized under NAICS code 541714 for scientific research and development services, and all communications must be directed to Contracting Officer Ethan Mauzy at the Department of Veterans Affairs office in Linthicum, Maryland. The solicitation number is 36C24526Q0624, and details are accessible via the SAM.gov website.
245-NETWORK Contract Office 5 (36C245)

POSTED

4 days ago

DEADLINE

in 12 days
View Details